Authors
Yong-Mei Zhang, Zhi-Min Zhang, Jie Zhou, Zhi-Lan Pan, Yan Yang, Xiao-Jun Zhao
Published in
Zhongguo shi yan xue ye xue za zhi. Volume 34. Issue 5. Pages 1341-1347.
Abstract
To investigate the correlation between the mRNA expression of cell division cycle 37 (CDC37) in bone marrow plasma cells of multiple myeloma (MM) patients and the efficacy of lenalidomide+bortezomib+dexamethasone (RVd) chemotherapy.
A total of 88 newly diagnosed MM patients who received RVd chemotherapy at our hospital from May 2021 to May 2024 were included. The chemotherapy effect was evaluated after four cycles of the RVd regimen; all patients' clinical and laboratory data were collected, and the expression levels of CDC37 mRNA in bone marrow plasma cells were detected using reverse transcription quantitative polymerase chain reaction (RT-qPCR). Patients were divided into objective response and non-objective response groups based on chemotherapy outcomes, and the clinical and laboratory data of the two groups were compared. Logistic regression analysis was used to analyze the association between CDC37 mRNA expression levels and chemosensitivity. The objective response group was further divided into three subgroups: complete response (CR), very good partial response (VGPR), and partial response (PR), and Spearman's correlation analysis was used to analyze the relationship between CDC37 mRNA expression levels and chemotherapy efficacy. ROC curves were plotted to analyze the value of CDC37 mRNA expression levels in predicting the efficacy of RVd chemotherapy regimen in MM patients.
After chemotherapy, the objective response rate of the 88 patients was 85.23% (75/88), including CR 29.55% (26/88), VGPR 32.95% (29/88), and PR 22.73% (20/88); after grouping, comparative clinical data showed that the levels of β2-microglobulin in the objective response group were significantly lower than those in the non-objective response group, and the expression levels of plasma cell CDC37 mRNA were significantly higher in the objective response group than in the non-objective response group (P<0.05). Logistic regression analysis showed that the expression level of CDC37 mRNA was an independent promoting factor for objective response to chemotherapy in MM patients (OR=1.839, P<0.05). Spearman correlation analysis showed that there was a positive correlation between CDC37 mRNA expression levels and chemotherapy efficacy (r=0.663, P<0.001); ROC curve analysis showed that CDC37 mRNA expression levels had high value in early predicting the objective response of MM patients to RVd chemotherapy, with an AUC of 0.891, sensitivity of 85.33%, and specificity of 84.62%; moreover, CDC37 mRNA expression levels also had high value in predicting different chemotherapy efficacies (predicting CR with an AUC of 0.882, and predicting ≥VGPR with an AUC of 0.804).
Early detection of CDC37 mRNA expression levels in bone marrow plasma cells can evaluate the chemotherapy efficacy of the RVd regimen in patients with MM.
PMID:
43059231
Bibliographic data and abstract were imported from PubMed on 20 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 5
- Comments 0